dihydroergotamine (Britannia)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namedihydroergotamine (Britannia)
Drug Alias Namedihydroergotaminenasal DHE (Britannia)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 5-HT1 receptors modulatorsAdrenergic receptors alpha-2 antagonists
TargetsSerotonin 5-HT1 receptorsAdrenergic receptors alpha-2
Therapy Area/IndicationsMigraine Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBritannia Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBritannia Pharmaceuticals Ltd
Active IndicationsN/A
Inactive IndicationsMigraine Disorders

Other Information

ATC CodeN/A
Related LinksN/A